RUNX1 and myeloproliferative neoplasm: While RUNX1 alterations are infrequent in PV (2%) [5] and found in 10–37% of post-MPN AML patients [102,103,162,163,164], they were associated with an adverse mutational effect, confirming the pathogenic relevance for leukemic transformation in MPN [19].